Table 1.
Baseline Characteristics of the Overall Analysis Cohort and Stratified According to Cancer Therapy Regimen
| Variable | Overalla (N=323) | Doxorubicin (n=199) | Trastuzumab (n=71) | Doxorubicin+ Trastuzumab (n=53) |
|---|---|---|---|---|
| Age, y | 48 [41–57] | 49 [41–56] | 51 [44–58] | 43 [38–54] |
| Race | ||||
| Black | 81 (25.1) | 58 (29.2) | 7 (9.9) | 16 (30.2) |
| White | 224 (69.3) | 130 (65.3) | 60 (84.5) | 34 (64.1) |
| Other/unknown | 18 (5.6) | 11 (5.5) | 4 (5.6) | 3 (5.7) |
| Breast cancer side | ||||
| Left | 147 (45.6) | 91 (45.8) | 32 (45.7) | 24 (45.3) |
| Right | 157 (48.8) | 97 (48.7) | 37 (52.9) | 23 (43.4) |
| Bilateral | 18 (5.6) | 11 (5.5) | 1 (1.4) | 6 (11.3) |
| Metastases or recurrence | 4 (1.2) | 1 (0.5) | 3 (4.2) | 0 (0) |
| Breast cancer stage | ||||
| 1 | 69 (21.3) | 27 (13.6) | 32 (45.1) | 10 (18.9) |
| 2 | 178 (55.1) | 123 (61.8) | 28 (39.4) | 27 (50.9) |
| 3 | 69 (21.4) | 47 (23.6) | 6 (8.5) | 16 (30.2) |
| 4 | 7 (2.2) | 2 (1.0) | 5 (7.0) | 0 (0) |
| Radiation therapy | ||||
| None | 119 (37.0) | 72 (36.4) | 30 (42.2) | 17 (32.1) |
| Left‐sided | 97 (30.1) | 59 (29.8) | 19 (26.8) | 19 (35.8) |
| Right‐sided | 95 (29.5) | 61 (30.8) | 21 (29.6) | 13 (24.5) |
| Bilateral | 11 (3.4) | 6 (3.0) | 1 (1.4) | 4 (7.6) |
| LVEF, % | 53 [51–56] | 53 [50–56] | 53 [52–56] | 54 [53–57] |
| Body mass index, kg/m2 | ||||
| <25 | 128 (39.7) | 77 (38.7) | 30 (42.2) | 21 (39.6) |
| 25 to 30 | 97 (30.0) | 60 (30.1) | 20 (28.2) | 17 (32.1) |
| ≥30 | 98 (30.3) | 62 (31.2) | 21 (29.6) | 15 (28.3) |
| Systolic blood pressure, mm Hg | 126 [116–135] | 125 [115–135] | 128 [117–140] | 125 [116–134] |
| Diastolic blood pressure, mm Hg | 74 [69–81] | 75 [68–82] | 73 [68–81] | 74 [70–79] |
| Heart rate, beats per min | 79 [72–89] | 79 [72–89] | 80 [72–90] | 78 [74–87] |
| Current or prior smoking | 128 (40.0) | 83 (42.3) | 25 (35.2) | 20 (37.7) |
| History of diabetes mellitus | 27 (8.4) | 19 (9.5) | 6 (8.5) | 2 (3.8) |
| History of hypertension | 99 (30.7) | 60 (30.3) | 28 (39.4) | 11 (20.8) |
| History of hyperlipidemia or statin use | 70 (21.7) | 45 (22.6) | 14 (20.0) | 11 (20.8) |
| ACEI/ARB or β‐blocker use | 61 (18.9) | 43 (21.6) | 13 (18.3) | 5 (9.4) |
| ACEI use | 28 (8.7) | 21 (10.6) | 5 (7.0) | 2 (3.8) |
| ARB use | 22 (6.8) | 13 (6.5) | 8 (11.3) | 1 (1.9) |
| β‐Blocker use | 22 (6.8) | 17 (8.5) | 3 (4.2) | 2 (3.8) |
| hs‐cTnT, ng/L | 3 [3–4] | 3 [3–4] | 3 [3–5] | 3 [3–4] |
| NT‐proBNP, ng/L | 68 [37–124] | 58 [35–103] | 140 [79–236] | 60 [30–112] |
| GDF‐15, ng/L | 629 [509–892] | 698 [538–897] | 587 [425–945] | 580 [519–707] |
| PIGF, ng/L | 13 [10–16] | 13 [10–15] | 15 [11–17] | 13 [10–16] |
| Myeloperoxidase, pmol/L | 307 [219–457] | 303 [213–476] | 325 [241–436] | |
ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; GDF‐15, growth differentiation factor 15; hs‐cTnT, high‐sensitivity cardiac troponin T; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; PIGF, placental growth factor.
a
Patients with at least 1 available biomarker measurement at baseline and during at least 1 follow‐up visit were included. Values are expressed as count (percentage) for categorical variables and median [interquartile range] for continuous variables. Myeloperoxidase was not measured in the trastuzumab group.